Klebsiella pneumoniae Infections – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Klebsiella pneumoniae Infections – Pipeline Review, H1 2017’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections

The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects

The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Appili Therapeutics

Cellceutix Corp

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

ImmunoClin Corp

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Klebsiella pneumoniae Infections - Overview

Klebsiella pneumoniae Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Klebsiella pneumoniae Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development

Appili Therapeutics

Cellceutix Corp

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

FOB Synthesis Inc

ImmunoClin Corp

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Klebsiella pneumoniae Infections - Drug Profiles

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-824 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-1807 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1454 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FSI-1671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FSI-1686 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNeg Snare - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interleukin-22 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirandamycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOSO-95179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Onc-72 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTP-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RX-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXP-873 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Klebsiella pneumoniae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-6076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WLBU-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Klebsiella pneumoniae Infections - Dormant Projects

Klebsiella pneumoniae Infections - Discontinued Products

Klebsiella pneumoniae Infections - Product Development Milestones

Featured News & Press Releases

Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases

Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections

Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology

Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Appili Therapeutics, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Cellceutix Corp, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Debiopharm International SA, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Evaxion Biotech ApS, H1 2017

Klebsiella pneumoniae Infections – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Klebsiella pneumoniae Infections – Pipeline by FOB Synthesis Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by ImmunoClin Corp, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Melinta Therapeutics Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Nosopharm SAS, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Peptilogics Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Pfizer Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Phico Therapeutics Ltd, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Sarepta Therapeutics Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Shionogi & Co Ltd, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Soligenix Inc, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Syntiron LLC, H1 2017

Klebsiella pneumoniae Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Klebsiella pneumoniae Infections – Dormant Projects, H1 2017

Klebsiella pneumoniae Infections – Dormant Projects, H1 2017 (Contd..1), H1 2017

Klebsiella pneumoniae Infections – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports